Xiao Q, Liu Y, Li T, Wang C, He S, Zhai L, Yang Z, Zhang X, Wu Y, Liu Y. Viral oncogenesis in cancer: from mechanisms to therapeutics [J]. Signal Transduct Target Ther, 2025, 10(1): 151.
Xiao Q, Liu Y, Shu X, Li Y, Zhang X, Wang C, He S, Li J, Li T, Liu T, Liu Y. Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling [J]. Exp Hematol Oncol, 2025, 14(1): 69.
Zhao S H, Zhu Z M, Yang T, Gao D, Liu L H, Yang W, Wang X B, Zhao Y X, Li M, Gao Y N, Ma R J, Yang Y, Li H P, Li L, Ao X L, Xiao X B, Hu C L, Yuan S Z, Ding Y, Chen X L, He J X, Liu Y, Huang W R. Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma [J]. Leukemia, 2025.
Zhang X, Yang Z, Xie X, Li J, Xiao Q, Xu G, Ma B, Xie X, Liu Y, Zhai L, Tang Y, Fu H, He S, Liu T, Huang D, Zeng C, Zhou Y, Hu R, Guo B, Wang C, Liang S, Luo Q, Lv J, Nan Y, Li J, Li Q, Wang S, Wu Y, Liu Y. The single-cell immune landscape of HIV-associated aggressive B-cell lymphoma [J]. J Natl Cancer Cent, 2025, 5(2): 221-35.
Yang Z, Mao X, Zhu M, Chen S, Gao Z, Jiang T, Peng Y, Ren F, Wang H, Wang L, Wan S, Weng X, Wang C, Wu Y, Wang Y, Xu Y, Zhu J, Zhu M, Zhai Y, Jing H, Xiao M, Liu Y, Liu Y. Chinese expert consensus on flow cytometric detection of hematological malignant cells in tissue samples [J]. J Natl Cancer Cent, 2025, 5(1): 28-37.
Yang T, Lei H, Li J, Liang Y, Wang C, Liu J, Wu Y, Liu J, Zhou Q, Min H, Yang Z, Zhang X, Huang Y, Wei G, Zhang W, Wang M, Tang X, Liu Z, Chen Y, Zhou H, Gale R P, Wu Y, Liu Y. A Visual Nomogram Survival Prediction Model in Acquired Immune Deficiency Syndrome (AIDS)-Related Diffuse Large B-Cell Lymphoma [J]. J Med Virol, 2025, 97(5): e70359.
Xiao Q, Yu F, Yan L, Lao X, Liang X, Zhao H, Zhai L, Yang Z, Zhang X, Liu Y, Zhang F. The CD4/CD8 ratio is associated with T lymphocyte functions in long-term virally suppressed patients with HIV [J]. BMC Infect Dis, 2025, 25(1): 76.
Tang X, Jiang T, Guo B, Liu J, Wang C, Zhang Y, Chen S, Peng Y, Zhang X, Li J, Liu Y, Yang Z. Serum beta2-microglobulin level is associated with the survival of HIV-associated diffuse large B-cell lymphoma: a retrospective study from China [J]. Sci Rep, 2025, 15(1): 15870.
Shu X, Xiao Q, Liu Y, Li Y, Xie X, He S, Li J, Zhang X, Liu Y. Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification [J]. Biomolecules, 2025, 15(7): 993.
Quan X, Xiao Q, Luo J, Wang C, Zhou Y, Zeng C, Zhang X, Li J, Huang D, Hu C, Guo B, Chen S, Yang Z, Deng X, Liu Y. Ferroptosis and Dysfunction of CD3+CD4-CD8- T Cells are Associated with Poor Immune Reconstitution in HIV Patients [J]. Curr HIV Res, 2025.
Guo B, Quan X, Yang Z, Li J, Liu Y. Meta-analysis of the comparative efficacy and safety of new drugs in combination with chemotherapy in primary plasmoblastic lymphoma [J]. Clin Exp Med, 2025, 25(1): 103.
Yang Z, Chen S, Tang X, Wang J, Liu L, Hu W, Huang Y, Hu J, Xing X, Zhang Y, Li J, Lei H, Liu Y. Development and validation of machine learning-based prediction model for severe pneumonia: A multicenter cohort study [J]. Heliyon, 2024, 10(17): e37367.
Xu G F, Zeng Z, Zhang Z B, Zhang X M, Wang M, Xiao Q, Li J, Xie X Q, He S, Fu H H, Liu Y, Yang Z L, Chen Y, Shi J, Wang B, Qiu H Y, Zhou Q, Liu Y, Chen S N. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL [J]. J Cell Mol Med, 2024, 28(3): e18114.
Li T, Xiao P, Qiu D, Yang A, Chen Q, Lin J, Liu Y, Chen J, Zeng Z. NCX1/Ca(2+) promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFkappaB signaling pathway [J]. Cell Commun Signal, 2024, 22(1): 258.
Li J, Zhang Y, Liu Z, Yang Z, Liu L, Xu G, Yang Z, Xiong Y, Liu J, Zhang X, Xiang Y, Li Q, Nan Y, Li J, Wu Y, Liu Y. Increased SARS-CoV-2 reinfection frequency, attenuated severity, and risk factor analysis in patients with hematological malignancies [J]. J Infect, 2024, 89(3): 106233.
Li J, Chen R, Cao L, Liu Y, Zhang Y, Wei X, Liu Z, Yang Z, Liu L, Zhou M, Xu G, Chen L, Ding Y, Lei H, Liu L, Yang Z, Chen S, Zhang X, Tang Y, Fu H, He S, Xiao Q, Xie X, Li Q, Nan Y, Li J, Chen X, Liu Y. Risk factors for COVID-19 pneumonia in patients with hematological malignancies: a multi-center, prospective study in China [J]. Front Immunol, 2024, 15: 1408969.
Gao H, Zhang Z, Wang J, Jia Y, Zheng Y, Pei X, Zhai W, Zhang R, Chen X, Ma Q, Wei J, Yang D, Pang A, He Y, Feng S, Zhang H, Du X, Song X, Liu Y, Zou D, Jiang E. Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China [J]. Exp Hematol Oncol, 2024, 13(1): 88.
Fu H, Xie X, Zhai L, Liu Y, Tang Y, He S, Li J, Xiao Q, Xu G, Yang Z, Zhang X, Liu Y. CX43-mediated mitochondrial transfer maintains stemness of KG-1a leukemia stem cells through metabolic remodeling [J]. Stem Cell Res Ther, 2024, 15(1): 460.
Zhang Y, Chen S, Tang X, Peng Y, Jiang T, Zhang X, Li J, Liu Y, Yang Z. The role of KLRG1: a novel biomarker and new therapeutic target [J]. Cell Commun Signal, 2024, 22(1): 337.
Xiao L, Wang C, Ma S, Wang Y, Guan L, Wu J, Zhang W, Liu Y, Wu Y. Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China [J]. Infect Agent Cancer, 2024, 19(1): 12.
Ran L, Peng Y, Zhao M, Luo X, Chen S, Tang X, Zhang Y, Li L, Li L, Zhang W, Jiang T, Wu X, Hu R, Liu Y, Yang Z. Predictive model of the efficiency of hematopoietic stem cell collection in patients with multiple myeloma and lymphoma based on multiple peripheral blood markers [J]. Int J Lab Hematol, 2024, 46(6): 1068-76.
Wang C, Wu Y, Liu J, Min H, Huang Y, Wei G, Zhang W, Wang M, Tang X, Zhou H, Chen Y, Liu Y. Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: The Central and Western China AIDS Lymphoma League 001 study (CALL-001 study) [J]. Front Immunol, 2023, 14: 1153790.
Liang X, Hu R, Li Q, Wang C, Liu Y. Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era [J]. Exp Hematol, 2023, 122: 1-9.
Li J, Liu Y, Wei X, Liu Z, Yang Z, Liu L, Zhou M, Xu G, Chen L, Ding Y, Lei H, Yang Z, Chen S, Zhang X, Tang Y, Fu H, He S, Guo B, Liang X, Zhang L, Zhang W, Wu J, Wang C, Hu C, Hu R, Luo X, Quan X, Zeng C, Liang S, Liu T, Lv J, Luo Q, Qi Q, Xu L, Xiong Y, Liu J, Huang D, Xiao C, Liu J, Yang T, Xiang Y, Li Q, Nan Y, Li J, Zhang Y, Wu Y, Liu Y. Antibody responses to SARS-CoV-2 Omicron infection in patients with hematological malignancies: A multicenter, prospective cohort study [J]. J Med Virol, 2023, 95(12): e29300.
Wang C, Liu Y. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting [J]. J Hematol Oncol, 2023, 16(1): 20.
Wang C, Liang S, Quan X, Guo B, Huang D, Li J, Liu Y. HIV-associated Burkitt lymphoma in the combination antiretroviral therapy era: Real-world outcomes and prognostication [J]. EJHaem, 2023, 4(1): 100-7.
Liu Q, Yang T, Chen X, Liu Y. Clinical value of (18)F-FDG PET/CT in the management of HIV-associated lymphoma [J]. Front Oncol, 2023, 13: 1117064.
Li X, Chen Y, Sun A, Wang Y, Liu Y, Lei H. Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China [J]. BMC Med Inform Decis Mak, 2023, 23(1): 125.
二、承担和参与的科学研究项目
[1]国家自然科学基金面上项目（主持）：GJIC介导Rac1蛋白失活抑制白血病干细胞干性的作用及机制研究，批准号：81670100，起止时间：2017.01.01-2020.12.31，57万
[2]国家自然科学基金面上项目（主持）：上调白血病骨髓基质细胞与耐药白血病细胞间GJIC功能逆转白血病细胞耐药的作用及机制研究，批准号：81370594，起止时间：2014.01.01-2017.12.31，70万[3]国家自然科学基金青年项目（主持）：间隙连接蛋白Cx43磷酸化状态对白血病骨髓基质细胞GJIC功能的影响及作用机制研究，批准号：81000194，起止时间：2011.01.01-2013.12.31，10万
[4]国家卫健委新发突发传染病防控科技重大项目（子课题）：项目名称：艾滋病多并发症人群综合诊治新策略研究，子课题名称：艾滋病并发肿瘤综合诊治新策略研究，项目编号：2025ZD01905000（课题编号：2025ZD01905003），起止时间：2025.12.01-2028.11.30，承担经费240万
[5]重庆市科卫联合医学重大项目（主持）：淋巴肿瘤样本和信息共享平台、技术、标准建设与研究，批准号：2025DBXM002，起止时间：2025.01.01-2027.12.31，200万
[6]重庆市技术创新与应用发展专项重大项目（联合主持）：全光谱流式仪，批准号：CSTB2025TIAD-STX0007，起止时间：2025.06.06-2028.06.05，承担经费200万
[7]重庆市创新医疗器械应用示范项目（主持），维生素检测仪应用示范项目，批准号：CQEIC2024MDAD-050，起止时间：2024.09.01-2027.09.01，112万
[8]“重庆英才计划”项目（主持）：多组学联用探索HIV相关淋巴瘤的分子特征和发病机制，批准号：cstc2022ycjh-bgzxm0048，起止时间：2022.01.01-2024.12.31，40万
[9]重庆大学医工融合重点项目（主持）：基于人工智能的淋巴瘤辅助诊断及预后评估系统，批准号：2022CDJYGRH-001，起止时间：2022.09.01-2025.08.31，60万
[10]重庆市自然科学基金面上项目（主持）,多组学探索HIV相关DLBCL发病机制，批准号：CSTB2022NSCQ-MSX1150,起止时间：2022.08.01-2025.07.31，10万
[11]重庆大学中央高校医工融合一般项目（联合主持）,CLK2调节病毒诱导的炎症因子风暴研究,批准号：2021CDJYGRH-004，2021.07.01-2023.06.30，20万
三、相关奖励与荣誉
科研奖励
